Design efficiency in dose finding studies
Author
Abstract
Suggested Citation
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Mauro Gasparini & Jeffrey Eisele, 2000. "A Curve-Free Method for Phase I Clinical Trials," Biometrics, The International Biometric Society, vol. 56(2), pages 609-615, June.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Pavel Mozgunov & Rochelle Knight & Helen Barnett & Thomas Jaki, 2021. "Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study," IJERPH, MDPI, vol. 18(1), pages 1-19, January.
- Oron Assaf P. & Azriel David & Hoff Peter D., 2011. "Dose-Finding Designs: The Role of Convergence Properties," The International Journal of Biostatistics, De Gruyter, vol. 7(1), pages 1-17, October.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Guosheng Yin & Ying Yuan, 2009. "Bayesian dose finding in oncology for drug combinations by copula regression," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(2), pages 211-224, May.
- Ying Kuen Cheung, 2002. "On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance," Biometrics, The International Biometric Society, vol. 58(1), pages 237-240, March.
- Ying Kuen Cheung & Rick Chappell, 2002. "A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method," Biometrics, The International Biometric Society, vol. 58(3), pages 671-674, September.
- Mezzetti, Maura & Muliere, Pietro & Bulla, Paolo, 2007. "An application of reinforced urn processes to determining maximum tolerated dose," Statistics & Probability Letters, Elsevier, vol. 77(7), pages 740-747, April.
- Guosheng Yin & Yisheng Li & Yuan Ji, 2006. "Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios," Biometrics, The International Biometric Society, vol. 62(3), pages 777-787, September.
- Drovandi, Christopher C. & McGree, James M. & Pettitt, Anthony N., 2013. "Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete data," Computational Statistics & Data Analysis, Elsevier, vol. 57(1), pages 320-335.
- Linda M. Haines & Inna Perevozskaya & William F. Rosenberger, 2003. "Bayesian Optimal Designs for Phase I Clinical Trials," Biometrics, The International Biometric Society, vol. 59(3), pages 591-600, September.
- Tian, Guo-Liang & Ng, Kai Wang & Tan, Ming, 2008. "EM-type algorithms for computing restricted MLEs in multivariate normal distributions and multivariate t-distributions," Computational Statistics & Data Analysis, Elsevier, vol. 52(10), pages 4768-4778, June.
- Peter F. Thall & Hoang Q. Nguyen & Ralph G. Zinner, 2017. "Parametric dose standardization for optimizing two-agent combinations in a phase I–II trial with ordinal outcomes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 66(1), pages 201-224, January.
- Guosheng Yin & Ying Yuan, 2009. "A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents," Biometrics, The International Biometric Society, vol. 65(3), pages 866-875, September.
- Ying Yuan & Guosheng Yin, 2009. "Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 58(5), pages 719-736, December.
- John O'Quigley, 2002. "Curve-Free and Model-Based Continual Reassessment Method Designs," Biometrics, The International Biometric Society, vol. 58(1), pages 245-249, March.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:csdana:v:45:y:2004:i:2:p:197-214. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/locate/csda .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.